Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 5Iodine-131 3Fluorodeoxyglucose F18 3trametinib 2pazopanib 2belinostat 2Vemurafenib 2Trastuzumab 2Specimen Handling 2Sirolimus 2Paclitaxel 2Fluorouracil 2FAPI-46 2Docetaxel 2Cyclophosphamide 2Cisplatin 2Cetuximab 2Biopsy 2Bevacizumab 2Azacitidine 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1romidepsin 1pembrolizumab 1naporafenib 1mercaptoundecahydrododecaborate 1fludarabine phosphate 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Thyroid Neoplasms × Triiodothyronine × Clear all
NCT00004062 2013-12-19

Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 1 Completed
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡